GHK-Cu raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-19 and is reviewed periodically as new material appears.
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence found naturally in human plasma, saliva and urine. Loren Pickart reported the isolation of the free peptide in 1973 while studying factors that influenced the growth of aged liver cells in culture. The peptide was later shown to bind copper(II) with high affinity, and the metal-bound form became the focus of most subsequent research. Its concentration in circulation declines markedly with age, a pattern that is well documented, though the physiological consequences of that decline remain debated.
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
The sequence now called GHK was first reported in the early 1970s after isolation from human plasma, where it was noted to influence liver cell behavior in laboratory preparations. Later work described a copper-binding form and its activity in fibroblast and wound-model experiments. Review articles frequently group the substance with other copper peptides. Concentrations in blood appear to fall with age in several small surveys, although the reason for this trend is not settled. Whether such a decline carries functional consequences remains an open question.
Published work on GHK-Cu concentrates largely on cell culture systems rather than whole organisms. Frequently used endpoints include collagen synthesis, expression of matrix metalloproteinases, and migration of fibroblasts. Some reports describe antioxidant behavior, while others stress delivery of copper into cells. These mechanisms are proposed rather than demonstrated, and the relative weight of each pathway is unclear. Human trials are few and generally small, so laboratory findings should not be read as confirmed clinical results.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide backbone consists of glycine, histidine, and lysine joined in that order. Copper is held through the imidazole nitrogen of histidine and the alpha-amino group at the N-terminus, which together produce a square-planar arrangement around the metal center. The solid appears blue to violet, a color that originates from d-d electronic transitions within the copper coordination sphere. The complex is indexed under CAS number 89030-95-5.
| Property | Value | Notes |
|---|---|---|
| INCI name | Copper tripeptide-1 | Standard designation on cosmetic ingredient labels |
| Peptide sequence | Gly-His-Lys | Three-residue ligand; binding occurs at the histidine side chain |
| Metal-to-peptide ratio | 1 to 1 | One copper(II) ion per peptide unit |
| Appearance | Blue to violet powder | Colour arises from copper-to-peptide electronic transitions |
| Water solubility | Freely soluble | Commonly formulated in aqueous or water-alcohol systems |
Material described as GHK-Cu appears in several distinct markets, including cosmetic ingredients, laboratory reagents, and consumer products, and the quality expectations attached to each differ. A certificate of analysis generally reports peptide purity by chromatography, copper content, appearance, and residual solvents or counterions. Counterion identity matters, because the complex is usually supplied as an acetate or a similar salt, and the counterion contributes to the measured mass. Independent verification of sequence and metal stoichiometry is advisable when a material is used for quantitative work. Batch-to-batch variation is common and should be documented rather than assumed negligible.
Copper peptide solutions tend to resist degradation better than many free peptides, because the bound metal protects the N-terminus and reduces susceptibility to some peptidases. Backbone hydrolysis, oxidation of the histidine imidazole ring, and photochemical reactions remain the principal degradation routes. Aqueous solutions are generally most stable near neutral to mildly acidic pH, while strongly alkaline conditions accelerate hydrolysis. Light exposure is usually avoided, since both the peptide and the copper center can take part in photochemical processes. Stability data published by suppliers often describe short-term behavior rather than multi-year shelf life.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, frequently paired with mass spectrometry to confirm the molecular ion. Copper content is measured separately, typically by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the chromatographic signal reports the peptide rather than the metal. Ultraviolet-visible spectroscopy provides a fast check on complex formation, since copper(II) peptide complexes absorb in the visible region. Elemental analysis and amino acid analysis are used less often but remain useful for reference standards. A gap between reported peptide purity and measured copper content is a recurring source of confusion.
Solid material is typically kept as a lyophilised powder in a sealed, light-protected container at minus 20 degrees Celsius, with desiccant where humidity is high. Working solutions are often prepared fresh, aliquoted and frozen to avoid repeated freeze-thaw cycles. Glassware and buffers are checked for trace metal contamination, since other transition metals can displace copper. Records of lot number, reconstitution date and storage temperature help trace unexpected colour changes. Blue colour itself is not a reliable purity test, because partly degraded solutions can remain visibly coloured.
Identity and purity are normally checked by reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry. The peptide absorbs in the ultraviolet region, and the copper complex also shows a broad visible absorption band that can be followed spectroscopically. Copper content is measured separately, for example by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not confirm how much metal is bound. Purity figures therefore need a stated basis: peptide peak area, copper content, or both.
The Scientific Research Publishing (SCIRP) is a predatory academic publisher of open-access electronic journals, conference proceedings, and scientific anthologies that are of questionable quality. As of December 2014, it offered 244 English-language open-access journals in the areas of science, technology, business, economy, and medicine. The company has been accused of using email spam to solicit papers for submission. Although it has an address in southern California, according to Jeffrey Beall it is a Chinese operation. In 2014 there was a mass resignation of the editorial board of one of the company's journals, Advances in Anthropology, with the outgoing editor-in-chief saying of the publisher "For them it was only about making money. We were simply their 'front'."
In 2018 Carlisle played 17 matches (4 wins, 1 draw and 12 losses) with the Saints' rebuild taking a backwards step. Carlisle would have played more games, but was suspended for two matches for striking Richmond's Jack Riewoldt and suffered a punctured lung in another incident after a mistake by club doctors. Carlisle managed only 10 games for the 2019 season due to injury, requiring surgery on his back for a protruding disc prior to the commencement of the season. He eventually returned in round 14 and played 10 consecutive games as the Saints transitioned to new coach Brett Ratten. Carlisle triggered an automatic 1-year contract extension upon reaching a games clause. Carlisle played 13 of a possible 19 games in a COVID-interrupted season, including the Saints' elimination final win against the Western Bulldogs. Carlisle was unable to play in the Saints' semi final game against Richmond due to the birth of his third child. Carlisle signed a further 1-year contract at the end of the year to remain at the club for the 2021 season. Carlisle was not selected for the first two rounds of the year, despite being available. He eventually returned to the side in Round Three, and played four consecutive games including an influential game against Port Adelaide in Round Six. This would consequently be his last AFL match. Carlisle suffered a back complaint during training ahead of Round Seven, and eventually was sent for surgery in mid May.
== Uses == Oclacitinib is labeled to treat atopic dermatitis and itchiness (pruritus) caused by allergies in dogs, though it has also been used to reduce the itchiness and dermatitis caused by flea infestations. While some say it is best only for acute flares of itchiness, others claim that it is also useful in chronic atopic dermatitis. It is considered to be highly effective in dogs and has been established as safe for at least short-term use. Its efficacy is comparable to prednisolone early in treatment, and although oclacitinib has been shown to be more effective in the short term for itchiness and dermatitis, its long-term safety is incompletely established. It has been found to have a faster onset and cause less gastrointestinal issues than cyclosporine. There is some off-label use of oclacitinib to treat asthma and allergic dermatitis in cats, but its efficacy has not been established.
=== Inhibitors of NF-κB activity === Concerning known protein inhibitors of NF-κB activity, one of them is IFRD1, which represses the activity of NF-κB p65 by enhancing the HDAC-mediated deacetylation of the p65 subunit at lysine 310, by favoring the recruitment of HDAC3 to p65. In fact IFRD1 forms trimolecular complexes with p65 and HDAC3. The NAD+-dependent protein deacetylase and longevity factor SIRT1 inhibits NF-κB gene expression by deacetylating the RelA/p65 subunit of NF-κB at lysine 310.
Sources: en.wikipedia.org
==== Amperometric glucose sensor ==== The electroanalysis of glucose is also based on the enzymatic reaction mentioned above. The produced hydrogen peroxide can be amperometrically quantified by anodic oxidation at a potential of 600 mV. The GOx is immobilized on the electrode surface or in a membrane placed close to the electrode. Precious metals such as platinum or gold are used in electrodes, as well as carbon nanotube electrodes, which e.g. are doped with boron. Cu–CuO nanowires are also used as enzyme-free amperometric electrodes, reaching a detection limit of 50 μmol/L. A particularly promising method is the so-called "enzyme wiring", where the electron flowing during the oxidation is transferred via a molecular wire directly from the enzyme to the electrode.
==== United States ==== Etizolam is not authorized by the FDA for medical use in the US. As of March 2016, etizolam is a controlled substance in the following states: Alabama, Arkansas, Florida, Georgia (as Schedule I), Louisiana, Mississippi, Texas, South Carolina, and Virginia. It is controlled in Indiana as of 1 July 2017. It is controlled in Ohio as of February 2018. On 23 December 2022, the DEA announced it had begun consideration on the matter of placing etizolam under temporary Schedule I status. Later on 25 July 2023, the DEA published a pre-print notice that etizolam would become temporarily scheduled as a Schedule I controlled substance from 26 July 2023 to 26 July 2025. On 25 July 2025, and effective the following day, the DEA extended the temporary scheduling until 26 July 2026. Effective 1 April 2026, etizolam is permanently in Schedule I under the Controlled Substances Act.
=== 7 August === Sudanese prosecutors charged Hemedti and 16 other TASIS leaders with committing war crimes in El Fasher and South Kordofan. Three SLM officials (Legal Advisor Mahmoud Koreina, Economic Affairs Advisor Adam al-Nur, and Media Advisor Mustafa al-Jamil) announced the formation of a splinter faction in Uganda following their dismissal by Minni Minawi. Eighteen people were killed in RSF attacks on the villages of Markaz Al-Ziyadia and Lamina al-Ziyadiyah in North Kordofan.
Anderson University* Master of Medical Science (MMS), Pathologists’ Assistant Studies Carroll University** Master of Science in Pathologists' Assistant Studies Drexel University* Master of Science in Pathologists’ Assistant Studies Duke University* Master of Health Science Loma Linda University* Master’s Degree in Health Science, Pathologists’ Assistant Medical University of South Carolina*** Master of Science in Pathologists' Assistant Studies Program Old Dominion University EVMS* Master of Health Sciences, Pathologists’ Assistant Quinnipiac University* Master of Health Science Rosalind Franklin University* Master of Science in Pathologists' Assistant Studies Touro University* Master of Science Tulane University* Master of Science in Anatomic Pathology University of Alberta* MSc with Specialization in Pathologists' Assistant University of Calgary* Master of Pathologists' Assistant University of Jamestown*** Master of Health Science University of Maryland Baltimore* Master of Science in Pathology University of Tennessee Health Science Center* Master's of Health Science (MHS) in Pathologists' Assistants University of Texas Medical Branch at Galveston* Master of Pathologists’ Assistant University of Toledo* Master of Science in Biomedical Science University of Toronto* Master of Health Science Degree in Laboratory Medicine - Pathologists’ Assistant Field University of Washington*** Master of Science in Anatomic Pathology University of Western Ontario* Master of Clinical Science in Pathologists' Assistant Studies Wayne State University* Master of Science in Pathologists' Assistant Studies West Virginia University* Master of Health Science As of 2/20/2026, the programs above have the following status with the National Accrediting Agency for Clinical Laboratory Sciences: |*| Accredited |**| Serious Applicant Status |***| Submitted documentation to become accredited
Acetyl (Ac), Benzoyl (Bz) groups — common in oligonucleotide synthesis for protection of N4 in cytosine and N6 in adenine. Removed by base, often aqueous or gaseous ammonia or methylamine. Too stable to readily remove from aliphatic amides. Troc (trichloroethoxycarbonyl) group – Removed by Zn insertion in the presence of acetic acid Tosyl (Ts) group – Removed by concentrated acid (HBr, H2SO4) & strong reducing agents (sodium in liquid ammonia or sodium naphthalenide) Other sulfonamide (Nosyl & Nps) groups — Removed by samarium iodide, thiophenol or other soft thiol nucleophiles, or tributyltin hydride Benzylamines:
Sources: en.wikipedia.org
It is a complex of a three-amino-acid peptide, glycine, histidine and lysine, bound to a single copper(II) ion. The metal is held mainly by the histidine side chain and the peptide backbone. Most commercial material is supplied as an acetate salt rather than as the free complex.
The free peptide was reported in 1973 by Loren Pickart, who isolated it from human plasma. Its copper-binding behaviour was characterised over the following years. The metal-bound form has been the subject of most later research.
Yes. Copper tripeptide-1 is the name used in cosmetic ingredient labelling, while GHK-Cu is the shorthand found in the scientific literature. Both refer to the same peptide-copper complex, and the two terms are interchangeable in most technical documents.
It is the copper complex of the tripeptide glycyl-L-histidyl-lysine. The metal ion is held by the histidine imidazole group and the peptide N-terminus. Most research on it concerns skin and wound models.